Last reviewed · How we verify

NCT03868332

Predictors of Subclinical Atherosclerotic Cardiovascular Diseases (ASCVD) in Patients With Inflammatory Bowel Disease

Status unknown Last updated 11 March 2019
What this trial tests

trial in Inflammatory Bowel Diseases in 80 participants. Status unknown.

Timeline
20 July 2019
Primary endpoint
20 March 2021
20 March 2021

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment80
Start date20 July 2019
Primary completion20 March 2021
Estimated completion20 March 2021

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart disease and failure are the major causes of mortality and morbidity worldwide, despite significant advances in medical technologies in the diagnosis and treatment of the disease. Cardiovascular disease may arise for various reasons including the steadily increasing incidence of obesity, type 2 diabetes, genetic, environmental, dietary and lifestyle factors. Besides all these, there is much evidence suggetsing that inflammation is an important player in the pathogenesis of heart disease, as well as atherogenesis and atherosclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03868332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing